Loading...
Loading...
In a report published Friday, Mizuho Securities analyst Peter Lawson reiterated a Buy rating and $22.00 price target on
EXACT Sciences CorporationEXAS.
In the report, Mizuho Securities noted, “Last night CMS issued preliminary reimbursement of $502 for Cologuard, above the approximately $350 we believe were in consensus sell-side models, and above the $400 from our investor survey — in line with Exact's proposal. The preliminary decision is a major positive for the stock and removes one of the two major elements from the bear thesis - uptake/commercializing being the second. We expect a 30-day comment period before a final pricing decision is made by year-end.”
EXACT Sciences Corporation closed on Thursday at $18.12.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in